Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

124.26 

-1.82 -1.4%

as of Aug 14 '20

52 Week Range:

86.95 154.24


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma. The company was founded in 2003 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) -2.33
0.76
3.33
19.32
21.50
22.11
25.50
28.69
41.23
52.65
54.41
growth rate 100.0% 338.2% 480.2% 11.3% 2.8% 15.3% 12.5% 43.7% 27.7% 3.3%
Earnings BIT -6.84
32.78
124.98
177.36
372.00
450.02
557.92
640.10
613.84
715.93
697.25
growth rate 100.0% 281.3% 41.9% 109.7% 21.0% 24.0% 14.7% -4.1% 16.6% -2.6%
Avg.PE -18.40
23.64
14.47
12.27
36.10
182.89
24.89
23.44
24.37
14.88
13.28
growth rate 100.0% -38.8% -15.2% 194.2% 406.6% -86.4% -5.8% 4.0% -38.9% -10.8%
ROA -6.08
26.96
64.21
26.00
10.29
2.09
9.84
9.73
9.83
8.66
9.74
growth rate 100.0% 138.2% -59.5% -60.4% -79.7% 370.8% -1.1% 1.0% -11.9% 12.5%
ROE 9.40
107.30
111.92
43.92
17.90
4.38
22.19
22.83
21.26
16.35
17.84
growth rate 1,041.5% 4.3% -60.8% -59.2% -75.5% 406.6% 2.9% -6.9% -23.1% 9.1%
ROIC 112.85
25.91
12.64
2.56
11.95
11.83
11.90
10.34
11.33
growth rate -77.0% -51.2% -79.8% 366.8% -1.0% 0.6% -13.1% 9.6%
Cur. Ratio 0.62
1.24
3.77
2.88
4.24
4.69
5.55
2.91
3.29
3.57
4.47
growth rate 100.0% 204.0% -23.6% 47.2% 10.6% 18.3% -47.6% 13.1% 8.5% 25.2%
Quick Ratio 0.47
1.12
3.64
2.42
3.73
4.01
5.29
2.56
2.81
3.15
3.93
growth rate 138.3% 225.0% -33.5% 54.1% 7.5% 31.9% -51.6% 9.8% 12.1% 24.8%
Leverage 4.44
1.32
1.75
1.73
2.44
2.10
2.56
1.89
1.89
1.78
growth rate -70.3% 32.6% -1.1% 41.0% -13.9% 21.9% -26.2% 0.0% -5.8%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 12.30
22.10
34.37
75.00
125.00
186.37
209.69
234.24
224.13
263.84
355.99
growth rate 79.7% 55.5% 118.2% 66.7% 49.1% 12.5% 11.7% -4.3% 17.7% 34.9%
Acct.Payable 39.91
16.00
21.00
25.13
21.81
22.42
24.37
40.60
47.55
growth rate -59.9% 31.3% 19.7% -13.2% 2.8% 8.7% 66.6% 17.1%
Cur.Assets 37.00
74.50
199.13
552.00
865.00
1,015.85
1,257.67
748.07
968.28
1,234.01
1,630.27
growth rate 101.4% 167.3% 177.2% 56.7% 17.4% 23.8% -40.5% 29.4% 27.4% 32.1%
Total Assets 107.40
135.70
253.57
1,966.00
2,238.00
3,338.96
3,332.61
4,800.23
5,123.67
5,203.49
5,538.90
growth rate 26.4% 86.9% 675.3% 13.8% 49.2% -0.2% 44.0% 6.7% 1.6% 6.5%
Cash 15.60
44.80
82.08
387.00
637.00
684.04
988.79
365.96
386.04
309.62
637.34
growth rate 187.2% 83.2% 371.5% 64.6% 7.4% 44.6% -63.0% 5.5% -19.8% 105.9%
Inventory 3.40
5.00
3.91
27.00
29.00
30.04
19.45
34.05
43.25
52.96
78.61
growth rate 47.1% -21.8% 590.7% 7.4% 3.6% -35.2% 75.1% 27.0% 22.5% 48.4%
Cur.Liabilities 59.20
59.90
52.87
192.00
204.00
216.80
226.64
257.41
293.95
345.49
364.49
growth rate 1.2% -11.7% 263.2% 6.3% 6.3% 4.5% 13.6% 14.2% 17.5% 5.5%
Liabilities 180.20
105.20
60.79
845.00
943.00
1,967.75
1,733.97
2,922.89
2,410.58
2,446.07
2,427.92
growth rate -41.6% -42.2% 1,290.2% 11.6% 108.7% -11.9% 68.6% -17.5% 1.5% -0.7%
LT Debt 91.10
24.60
0.00
427.00
544.00
1,333.00
1,150.86
1,993.53
1,540.43
1,563.03
1,574.53
growth rate -73.0% -100.0% 27.4% 145.0% -13.7% 73.2% -22.7% 1.5% 0.7%
Equity -72.83
30.60
192.79
1,121.29
1,295.53
1,371.14
1,598.65
1,877.34
2,713.10
2,757.42
3,110.98
growth rate 100.0% 530.0% 481.6% 15.5% 5.8% 16.6% 17.4% 44.5% 1.6% 12.8%
Common Shares 30.00
39.00
47.00
60.00
62.00
63.00
63.00
62.00
61.00
61.00
58.00
growth rate 30.0% 20.5% 27.7% 3.3% 1.6% 0.0% -1.6% -1.6% 0.0% -4.9%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 0.10
0.70
1.28
6.00
10.00
36.35
35.96
9.69
28.95
20.37
40.14
growth rate 600.0% 82.7% 369.1% 66.7% 263.5% -1.1% -73.1% 198.9% -29.6% 97.0%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -15.88
58.90
151.60
250.00
288.00
407.61
531.94
592.39
693.09
798.90
776.40
growth rate 100.0% 157.4% 64.9% 15.2% 41.5% 30.5% 11.4% 17.0% 15.3% -2.8%
FCF per Share -0.73
1.37
2.75
3.78
4.78
2.08
7.62
5.56
9.32
10.35
12.45
growth rate 100.0% 100.7% 37.5% 26.5% -56.5% 266.4% -27.0% 67.6% 11.1% 20.3%
Sale Purchase of Stock 16.42
25.00
-105.78
58.49
40.52
24.17
31.82
growth rate 52.3% -100.0% 100.0% -30.7% -40.3% 31.7%
FCF -22.00
54.00
146.00
227.00
272.00
167.00
496.00
409.00
579.00
667.00
594.00
growth rate 100.0% 170.4% 55.5% 19.8% -38.6% 197.0% -17.5% 41.6% 15.2% -10.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 128.40
173.80
272.28
586.00
872.00
1,172.88
1,324.80
1,487.97
1,618.69
1,890.92
2,161.76
growth rate 35.4% 56.7% 115.2% 48.8% 34.5% 13.0% 12.3% 8.8% 16.8% 14.3%
Op.Income 15.90
57.80
124.98
261.00
372.00
450.02
557.92
640.10
613.84
715.93
697.25
growth rate 263.5% 116.2% 108.8% 42.5% 21.0% 24.0% 14.7% -4.1% 16.6% -2.6%
IBT 0.00
0.00
124.98
177.36
307.95
151.56
435.93
532.07
440.11
527.26
450.21
growth rate 41.9% 73.6% -50.8% 187.6% 22.1% -17.3% 19.8% -14.6%
Net Income -6.80
32.80
124.98
261.00
216.00
58.39
329.54
396.83
487.85
447.10
523.37
growth rate 100.0% 281.1% 108.8% -17.2% -73.0% 464.4% 20.4% 22.9% -8.4% 17.1%
EPS -0.23
0.83
2.67
4.79
3.51
0.93
5.23
6.41
7.96
7.30
9.09
growth rate 100.0% 221.7% 79.4% -26.7% -73.5% 462.4% 22.6% 24.2% -8.3% 24.5%
Gross Profit 118.80
160.20
258.34
524.00
774.00
1,065.96
1,222.28
1,382.59
1,508.51
1,769.38
2,033.83
growth rate 34.9% 61.3% 102.8% 47.7% 37.7% 14.7% 13.1% 9.1% 17.3% 15.0%
R&D 36.60
25.60
14.12
20.48
41.63
85.18
133.45
160.40
198.44
226.62
299.73
growth rate -30.1% -44.8% 45.0% 103.3% 104.6% 56.7% 20.2% 23.7% 14.2% 32.3%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 206.48
184.88
116.15
148.72
growth rate -10.5% -37.2% 28.0%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 311.25
267.03
355.99
317.30
351.92
growth rate -14.2% 33.3% -10.9% 10.9%
Acct.Payable 82.22
70.10
47.55
66.31
50.04
growth rate -14.7% -32.2% 39.5% -24.5%
Cur.Assets 1,370.07
1,520.56
1,630.27
1,517.64
2,302.35
growth rate 11.0% 7.2% -6.9% 51.7%
Total Assets 5,488.66
5,527.85
5,538.90
5,215.30
6,066.50
growth rate 0.7% 0.2% -5.8% 16.3%
Cash 637.74
795.18
637.34
701.60
786.08
growth rate 24.7% -19.9% 10.1% 12.0%
Inventory 69.00
71.11
78.61
85.61
92.53
growth rate 3.1% 10.6% 8.9% 8.1%
Cur.Liabilities 369.49
390.44
364.49
396.12
409.96
growth rate 5.7% -6.7% 8.7% 3.5%
Liabilities 2,505.23
2,473.45
2,427.92
2,406.80
growth rate -1.3% -1.8% -0.9%
LT Debt 1,569.16
1,572.11
1,574.53
1,578.43
growth rate 0.2% 0.2% 0.3%
Equity 2,983.43
3,054.41
3,110.98
2,808.50
3,141.81
growth rate 2.4% 1.9% -9.7% 11.9%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 13.96
11.09
7.14
4.83
growth rate -20.6% -35.6% -32.3%
Cash Dividends
growth rate
Cash From OA 148.85
337.50
87.80
272.97
growth rate 126.7% -74.0% 210.9%
Sale Purchase of Stock
growth rate
FCF 134.88
326.42
80.66
268.14
growth rate 142.0% -75.3% 232.4%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 534.13
537.70
581.74
534.73
562.44
growth rate 0.7% 8.2% -8.1% 5.2%
Op.Income 206.48
184.88
116.15
148.72
growth rate -10.5% -37.2% 28.0%
IBT 183.25
113.18
39.47
-209.12
growth rate -38.2% -65.1% -100.0%
Net Income 261.90
102.28
73.99
-157.83
114.80
growth rate -61.0% -27.7% -100.0% 100.0%
EPS
growth rate
Gross Profit 506.46
506.30
546.39
506.07
growth rate 0.0% 7.9% -7.4%
R&D 62.38
79.86
97.38
86.11
growth rate 28.0% 22.0% -11.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (85.29)

YOY Growth Grade:

B (72.38)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 52.74 52.74 7.38
EPS / Growth 12.9% 2.36 7.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 31.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 7.0% 17.1% 17.1%
Future PE 7.38 31.45 31.45
Future EPS 4.61 11.43 11.43
Value Price
MOS %
8.41
-93.2%
88.86
-28.5%
88.86
-28.5%
MOS Price 4.21 44.43 44.43
IRT 22.14 13.68 13.68

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.